NSAID Label Revisions Likely Unavoidable Without New Trial Data – Jenkins
This article was originally published in The Tan Sheet
Executive Summary
NSAID marketers seeking substantial changes to revised labeling recently requested by FDA will likely need to submit new study data, according to the agency